Kara L. Davis
YOU?
Author Swipe
View article: Supplementary Data from A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412
Supplementary Data from A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412 Open
Supplementary information
View article: Supplementary fig 1 from A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412
Supplementary fig 1 from A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412 Open
Supplementary Figure 1. Nivolumab (A) and Ipilumumab (B) peak and trough concentrations in treatment cycles 1 – 4.
View article: Single-cell profiling of CD19-directed CAR-T cell phenotypes and immune system dynamics in pediatric B-cell acute lymphoblastic leukemia
Single-cell profiling of CD19-directed CAR-T cell phenotypes and immune system dynamics in pediatric B-cell acute lymphoblastic leukemia Open
Not available.
View article: A real-world multi-institution experience of standard vs alternative dosing of inotuzumab ozogamicin for Relapsed/Refractory pediatric B-cell acute lymphoblastic leukemia
A real-world multi-institution experience of standard vs alternative dosing of inotuzumab ozogamicin for Relapsed/Refractory pediatric B-cell acute lymphoblastic leukemia Open
Background: Inotuzumab ozogamicin (InO) is an active agent in children and adults with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). The FDA-approved dosing is 1.8 mg/m2/cycle fractionated into 3 doses, although re…
View article: 269 Humanized anti-CAR antibodies affect durable response to GD2-CAR T-cells in diffuse midline glioma
269 Humanized anti-CAR antibodies affect durable response to GD2-CAR T-cells in diffuse midline glioma Open
View article: Harmonization on defining B‐cell recovery post CD19‐CAR T‐cell therapy in B‐cell acute lymphoblastic leukemia: An international consensus statement
Harmonization on defining B‐cell recovery post CD19‐CAR T‐cell therapy in B‐cell acute lymphoblastic leukemia: An international consensus statement Open
Relapse following CD19‐targeting chimeric antigen receptor T‐cell therapy (CD19‐CAR) remains a major barrier to long‐term cure in relapsed/refractory B‐cell acute lymphoblastic leukemia, with nearly 50% of patients relapsing within 6 month…
View article: CTIM-05. HUMANIZED ANTI-CAR ANTIBODIES AFFECT DURABLE RESPONSE TO GD2-CAR T-CELLS IN DIFFUSE MIDLINE GLIOMA
CTIM-05. HUMANIZED ANTI-CAR ANTIBODIES AFFECT DURABLE RESPONSE TO GD2-CAR T-CELLS IN DIFFUSE MIDLINE GLIOMA Open
H3K27M-mutated diffuse midline gliomas (DMGs) are universally lethal cancers in children and young adults. Our team previously demonstrated efficacy of GD2-targeting chimeric antigen receptor (GD2-CAR) T-cells in preclinical models of DMG …
View article: In Response to <i>A Clinical Consensus Statement on Pulmonary Recurrent Respiratory Papillomatosis</i>
In Response to <i>A Clinical Consensus Statement on Pulmonary Recurrent Respiratory Papillomatosis</i> Open
View article: Annotation-free discovery of disease-relevant cells in single-cell datasets
Annotation-free discovery of disease-relevant cells in single-cell datasets Open
In single-cell datasets, patient labels indicating disease status (e.g., “sick” or “not sick”) are typically available, but individual cell labels indicating which of a patient’s cells are associated with their disease state are generally …
View article: CellFuse Enables Multi-modal Integration of Single-cell and Spatial Proteomics data
CellFuse Enables Multi-modal Integration of Single-cell and Spatial Proteomics data Open
Single-cell and spatial proteomic technologies capture complementary biological information, yet no single platform can measure all modalities within the same cell. Most existing integration methods are optimized for transcriptomic data an…
View article: IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignancies
IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignancies Open
View article: Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia
Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia Open
Lineage switch (LS), defined as the immunophenotypic transformation of acute leukemia, has emerged as a mechanism of relapse after antigen-targeted immunotherapy, which is associated with dismal outcomes. Through an international collabora…
View article: Single-cell profiling of CAR-T CD19 cell phenotypes and immune system dynamics in pediatric BCP-ALL
Single-cell profiling of CAR-T CD19 cell phenotypes and immune system dynamics in pediatric BCP-ALL Open
Background Chimeric Antigen Receptor T-cell (CAR-T) therapy targeting CD19 has transformed the treatment of relapsed/refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, the phenotypic heterogeneity of CAR+ T-cells …
View article: Uridine Metabolism as a Targetable Metabolic Achilles’ Heel for chemo-resistant B-ALL
Uridine Metabolism as a Targetable Metabolic Achilles’ Heel for chemo-resistant B-ALL Open
Relapse continues to limit survival for patients with B-cell acute lymphoblastic leukemia (B-ALL). Previous studies have independently implicated activation of B-cell developmental signaling pathways and increased glucose consumption with …
View article: Author Correction: Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas
Author Correction: Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas Open
View article: Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas
Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas Open
View article: IKAROS facilitates antigen escape in the face of CD19- and CD22-targeted therapies for B-cell acute lymphoblastic leukemia
IKAROS facilitates antigen escape in the face of CD19- and CD22-targeted therapies for B-cell acute lymphoblastic leukemia Open
Summary Relapse due to antigen escape is a major cause of treatment failure for patients with B-cell malignancies following targeted immunotherapies, including CD19- and CD22-directed chimeric antigen receptor T (CAR T) cells. To identify …
View article: GLUT1 overexpression in CAR-T cells induces metabolic reprogramming and enhances potency
GLUT1 overexpression in CAR-T cells induces metabolic reprogramming and enhances potency Open
View article: Case report: sub-clinical extramedullary B-ALL in the setting of relapse following targeted therapy
Case report: sub-clinical extramedullary B-ALL in the setting of relapse following targeted therapy Open
Standard testing for disease evaluation in B-cell acute lymphoblastic leukemia (B-ALL) includes examination of the bone marrow and cerebrospinal fluid. Radiographic or functional imaging are indicated when clinical signs of non-CNS extrame…
View article: CNS-wide repopulation by hematopoietic-derived microglia-like cells corrects progranulin deficiency in mice
CNS-wide repopulation by hematopoietic-derived microglia-like cells corrects progranulin deficiency in mice Open
View article: CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study
CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study Open
View article: Sequential intravenous and intracerebroventricular GD2-CAR T-cell therapy for H3K27M-mutated diffuse midline gliomas
Sequential intravenous and intracerebroventricular GD2-CAR T-cell therapy for H3K27M-mutated diffuse midline gliomas Open
H3K27M-mutant diffuse midline gliomas (DMGs) express high levels of the GD2 disialoganglioside and chimeric antigen receptor modified T-cells targeting GD2 (GD2-CART) eradicate DMGs in preclinical models. Arm A of the Phase I trial NCT0419…
View article: IMMU-13. TUMOR INFLAMMATION-ASSOCIATED NEUROTOXICITY (TIAN): A TOXICITY SYNDROME IN PATIENTS TREATED WITH IMMUNOTHERAPY FOR CENTRAL NERVOUS SYSTEM TUMORS
IMMU-13. TUMOR INFLAMMATION-ASSOCIATED NEUROTOXICITY (TIAN): A TOXICITY SYNDROME IN PATIENTS TREATED WITH IMMUNOTHERAPY FOR CENTRAL NERVOUS SYSTEM TUMORS Open
BACKGROUND Immunotherapies are increasingly being explored as potential therapeutic modalities for the treatment of central nervous system (CNS) tumors and have unique toxicity profiles. Toxicity syndromes such as cytokine release syndrome…
View article: DIPG-47. SEQUENTIAL INTRAVENOUS AND INTRACEREBROVENTRICULAR GD2-CAR T-CELL THERAPY FOR H3K27M-MUTATED DIFFUSE MIDLINE GLIOMAS
DIPG-47. SEQUENTIAL INTRAVENOUS AND INTRACEREBROVENTRICULAR GD2-CAR T-CELL THERAPY FOR H3K27M-MUTATED DIFFUSE MIDLINE GLIOMAS Open
BACKGROUND H3K27M-mutant diffuse midline gliomas (DMGs) express uniformly high levels of the GD2 disialoganglioside. In preclinical models, chimeric antigen receptor modified T-cells (CAR T-cells) targeting GD2 robustly regressed orthotopi…
View article: CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results
CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results Open
View article: Inosine induces stemness features in CAR-T cells and enhances potency
Inosine induces stemness features in CAR-T cells and enhances potency Open
Adenosine (Ado) mediates immune suppression in the tumor microenvironment and exhausted CD8+ CAR-T cells express CD39 and CD73, which mediate proximal steps in Ado generation. Here, we sought to enhance CAR-T cell potency by kno…
View article: Stem cell transplantation for ALL: you've always got a donor, why not always use it?
Stem cell transplantation for ALL: you've always got a donor, why not always use it? Open
Hematopoietic stem cell transplantation (HSCT) represents a consolidated therapeutic strategy for high-risk pediatric acute lymphoblastic leukemia (ALL), offering the potential for curative treatment. This manuscript delves into the debate…
View article: Genome editing–induced t(4;11) chromosomal translocations model B cell precursor acute lymphoblastic leukemias with KMT2A-AFF1 fusion
Genome editing–induced t(4;11) chromosomal translocations model B cell precursor acute lymphoblastic leukemias with KMT2A-AFF1 fusion Open
A t(4;11) leukemia model established from CRISPR-engineered chromosomal translocations between the KMT2A and AFF1 genes recapitulate proteomic, epigenomic, and transcriptomic features of primary patient leukemias.
View article: 275 Inosine endows CAR T cells with features of increased stemness and anti-tumor potency
275 Inosine endows CAR T cells with features of increased stemness and anti-tumor potency Open
Background CAR T cells have been highly effective against refractory B cell malignancies but have not demonstrated sustained antitumor effects against solid tumors. Intense effort is underway to augment the potency of CAR T cells in order …
View article: A Pilot Study of Plasma Microbial Cell-Free DNA Following Chimeric Antigen Receptor T Cell Therapy in Pediatric Patients with Relapsed/Refractory Leukemia
A Pilot Study of Plasma Microbial Cell-Free DNA Following Chimeric Antigen Receptor T Cell Therapy in Pediatric Patients with Relapsed/Refractory Leukemia Open
Chimeric antigen receptor (CAR) T cell therapy is a promising treatment for pediatric patients with relapsed or refractory B cell acute lymphoblastic leukemia (R/R B ALL). Cytokine release syndrome (CRS) is a common toxicity after CAR T ce…